Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503278 | 1.00 | CA1 (0.50) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL8906230 | 0.83 | CA14 (0.33) | CA1CA2CA7CA12CA14 | |
| SCHEMBL8907625 | 0.83 | CA14 (0.33) | CA1CA2CA7CA12CA14 | |
| SCHEMBL19318523 | 0.83 | CA14 (0.33) | CA1CA2CA7CA12CA14 | |
| SCHEMBL19750452 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23607312 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL1371004 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL1369240 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL148100 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23849248 | 0.81 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CA1 3384/4885CA2 3833/4885CA7 3439/4885 |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | CA1 1736/4885CA2 4361/4885CA7 2306/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CA1 4702/4885CA2 4687/4885CA7 4332/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CA1 3384/4885CA2 3833/4885CA7 3439/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | CA1 3384/4885CA2 3833/4885CA7 3439/4885 |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | CA1 3810/4885CA2 4131/4885CA7 3418/4885 |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | CA1 463/4885CA2 3245/4885CA7 1439/4885 |
| US-20230043447-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | CA1 1736/4885CA2 4361/4885CA7 2306/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | CA1 706/4885CA2 646/4885CA7 772/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | CA1 1306/4885CA2 3825/4885CA7 2015/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CA1 4787/4885CA2 4742/4885CA7 4307/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | CA1 4800/4885CA2 4745/4885CA7 4324/4885 |
| US-20210220477-A1 | SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | CD2BP2, DNPEP, LNPEP | CA1 1306/4885CA2 3825/4885CA7 2015/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | CA1 1736/4885CA2 4361/4885CA7 2306/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | CA1 2585/4885CA2 4349/4885CA7 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.